Exelixis, Inc. (NASDAQ:EXEL)’s shares dropped 1.65% to $3.50. The company on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Exelixis, Inc. (NASDAQ:EXEL), shares after opening at $3.51 moved to $3.59 on last trade day and at the end of the day closed at $3.37. Company price to sales ratio in past twelve months was calculated as 20.95 and price to cash ratio as 2.57. Exelixis, Inc. (NASDAQ:EXEL), showed a negative weekly performance of 6.91%.
On April 8, 2014, Hercules Offshore, Inc. (Nasdaq:HERO) announced that it has scheduled a conference call to discuss its first quarter 2014 financial results on April 23, 2014. The call will take place at 10:00 a.m. CDT (11:00 a.m. EDT). The financial results are scheduled to be released publicly prior to market opening in the United States on that same day. Hercules Offshore, Inc. (NASDAQ:HERO), shares fell 1.83% in last trading session and ended the day on $4.30. Hercules Offshore, Inc. (NASDAQ:HERO), return on equity ratio is recorded as -7.60% and its return on assets is -3.10%. Hercules Offshore, Inc. (NASDAQ:HERO), yearly performance is -40.93%.
Investment analysts at Mizuho lowered their price objective on shares of Aeropostale (NYSE:ARO) from $7.00 to $5.00 in a note issued to investors on Friday, American Banking & Market News reports. The firm currently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential upside of 2.04% from the stock’s previous close. Aeropostale Inc (NYSE:ARO), shares moved down 4.62% in last trading session and was closed at $5.71, while trading in range of $ 4.51 – 4.79. Aeropostale Inc (NYSE:ARO), year to date (YTD) performance is -49.17%.
Antares Pharma (Nasdaq:ATRS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and deteriorating net income. Antares Pharma Inc (NASDAQ:ATRS), weekly performance is -12.93%. On last trading day company shares ended up $3.03. Antares Pharma Inc (NASDAQ:ATRS), distance from 50-day simple moving average (SMA50) is -27.28%. Analysts mean target Price for the company is $6.30.
Leave a Reply